Deep Vein Thrombosis

Thrombophlebitis:

  • Condition in which a blood clot forms and blocks one or more veins.

  • Superficial thrombophlebitis: Blockage near the skin surface.

  • Deep venous thrombosis (DVT): Thrombosis located in a muscle

    • Occur in deep veins leading to the vena cava

    • Typically found in the legs, especially calves (most hospitable environment).

      • Deep veins in arms, chest, neck are not typical locations for thrombus formation.

    • Approximately 50% of DVTs are asymptomatic.

    • Symptoms depend on clot location and size.

Pathophysiology

  • Thrombi:

    • Arterial thrombi: Occur at sites of arterial plaque rupture.

    • Venous thrombi: Occur when there's low blood flow within normal vein conditions.

  • DVT

    • Virchow triad: Three pathological factors associated with thrombus formation.

      • Circulatory stasis: Stagnation of blood flow contributes to clot formation.

      • Vascular damage: Damage to veins stimulates the clotting cascade.

      • Hypercoagulability: Increased tendency of blood to clot.

  • Vascular damage stimulates the clotting cascade, leading to thrombus propagation in the direction of blood flow, triggering an inflammatory response.

  • Thrombus behavior:

    • Thrombus may float within a vein.

    • Pieces may break loose, traveling as emboli through the circulation.

    • Fibroblasts invade the thrombus, scar the vein, and can destroy venous valves.

    • Damage may be permanent, affecting normal blood flow even if valve patency is restored.

Risk Factors

  • Thrombi

    • Commonly a complication of hospitalization, surgery, immobilization.

    • Other predisposing factors include:

    • Venous injury.

    • Cancer.

    • Pregnancy.

    • Use of oral contraceptives or hormone replacement therapy (HRT).

    • Clotting disorders.

    • Obesity.

    • Personal and family history of venous thromboembolism.

  • DVT

    • Orthopedic procedures.

    • Atrial fibrillation.

    • Acute myocardial infarction.

    • Ischemic stroke.

DVT Prevention

  • Maintaining a healthy weight.

  • Regular walking to encourage circulation.

  • Staying hydrated to reduce the risk of clotting.

  • Refraining from immobility: stand up and walk around every hour.

  • Avoiding leg crossing while sitting.

  • Avoiding smoking and excessive alcohol consumption.

  • Prophylaxis:

    • Low-molecular-weight heparins (LMWH).

    • Oral anticoagulation.

    • Elevating foot of bed while keeping knees slightly flexed.

    • Early mobilization following procedures or during illness.

    • Leg exercises and use of elastic stockings or pneumatic compression devices.

Manifestations

  • Leg pain: 90%

  • Tenderness: 85%

  • Ankle edema: 76%

  • Calf swelling: 42%

  • Dilated veins: 33%

  • Homan's sign (sharp pain in the calf on dorsiflexion of the foot): 33%

  • Often asymptomatic or symptoms may vary in severity.

  • Typical symptoms include aching pain in the affected extremity especially when walking.

  • Possible tenderness, warmth, erythema, cyanosis, and edema.

  • Rarely, a palpable cord may be felt along the affected vein.

Diagnosis

  • Wells Score

    • Wells score ≥ 2 points = DVT likely

    • Wells score ≤ 1 point = DVT unlikely

    • For suspected DVT:

      • Determine the 2-level DVT Wells score.

      • If suspecting DVT, a vein ultrasound scan should be done within 4 hours or a D-dimer test if not previously performed.

      • If DVT is confirmed with ultrasound, therapeutic anticoagulation is started.

      • If D-dimer is positive but DVT is unlikely, appropriate follow-up is initiated with repeat scanning.

    • Wells Score Criteria:

      • Active cancer (treatment ongoing, within 6 months, or palliative): 1 point.

      • Paralysis, paresis, or recent plaster immobilization of lower extremities: 1 point.

      • Recently bedridden for 3 days or more, or major surgery within 12 weeks requiring general or regional anesthesia: 1 point.

      • Localized tenderness along the distribution of the deep venous system: 1 point.

      • Entire leg swollen: 1 point.

      • Calf swelling > 3 cm compared to the asymptomatic leg: 1 point.

      • Pitting edema confined to the symptomatic leg: 1 point.

      • Collateral superficial veins (non-varicose): 1 point.

      • Previously documented DVT: 1 point.

      • An alternative diagnosis is at least as likely as DVT: -2 points.

  • Laboratory Studies:

    • D-dimer test.

    • Prothrombin time (PT).

    • Partial thromboplastin time (PTT).

    • Activated partial thromboplastin time (aPTT).

    • Bleeding time.

    • Platelet count.

  • Imaging Tests:

    • Duplex venous ultrasonography.

    • Plethysmography.

    • MRI.

    • Ascending contrast venography.

Treatment

Pharmacologic Therapy

  • Thrombolytic drugs are used to accelerate clot lysis, particularly in patients with serious complications and low risk of bleeding.

  • NSAIDs to reduce inflammation in veins and provide symptom relief, especially in patients with superficial venous thrombosis.

  • Anticoagulants:

    • Heparin:

      • Dosage is calculated to maintain aPTT at twice the control or normal value.

      • Usually administered as a continuous infusion or subcutaneously as an alternative.

    • Warfarin:

      • Used in combination with IV heparin for 4–5 days until INR is stabilized.

      • Takes up to 5 days for full effects.

      • Dosages adjusted to maintain INR > 2.0.

      • Regular follow-up and maintenance dose to prevent recurrent thrombosis.

      • Continue therapy for at least 3 months.

    • LMWH:

      • More effective with a lower risk of bleeding and do not require close laboratory monitoring.

      • Administered subcutaneously in fixed doses.

  • Direct thrombin inhibitors:

    • Inactivate free and bound thrombin; limited use in specific cases.

  • Factor Xa inhibitors:

    • Disrupt coagulation cascade directly, useful in treating and preventing DVT, and protecting against stroke in patients with atrial fibrillation.

    • Competitive with warfarin and have advantages, including fewer dietary interactions and avoidance of frequent INR monitoring.

    • Consider risks of serious ischemic events when discontinuing without alternatives.

Surgical

  • Venous thrombectomy:

    • Performed when thrombus lodges in the femoral vein to prevent PE or gangrene.

    • Duration of effect can vary between patients.

  • Filters:

    • Placed for recurrent thrombosis when anticoagulation is contraindicated.

  • Vein ligation:

    • Aims to prevent clot extension into the deep venous system.

Nonpharmacologic

  • Application of warm, moist compresses on the affected area.

  • Resting the extremity and elevation above heart level.

  • Use of anti-inflammatory agents.

  • Bed rest advised, with legs elevated above the heart.

  • Initiate walking when permitted, avoiding tight clothing or stockings.

Complications

  • Recurrence of DVT

  • Pulmonary embolism (PE; clot or fragments travel to pulmonary circulation)

Lifespan Considerations

  • Infants and Children:

    • DVT is rare but risk factors include prematurity and infection.

    • Symptoms often nonspecific and may involve acute pain and swelling.

    • Treatment with unfractionated heparin or LMWH is common, transitioning to oral warfarin when appropriate.

  • Adolescents and Young Adults:

    • Increased risk especially in females using hormonal contraceptives.

    • Symptoms include swelling, pain, and warmth; diagnosis and treatment are similar to adults.

    • Precaution against teratogenic effects of anticoagulant drugs, as they can affect pregnancy outcomes.

  • Pregnant Women:

    • Higher risks during pregnancy and the postpartum period.

    • Preferred use of heparin; monitoring for complications and progress is crucial.

    • Transitioning to warfarin postpartum poses risks that require careful monitoring.

  • Older Adults:

    • Increased risk of DVT and comorbidities complicate management.

    • Often asymptomatic or exhibit nonspecific signs.

    • Assessments must consider age-related factors affecting test results and treatment outcomes.